RetelliptineAlternative Names: BD 84; SR 95325; SR 95325A; SR 95325B
Latest Information Update: 05 Dec 1994
At a glance
- Originator Sanofi-Synthelabo
- Class Antineoplastics; Indole alkaloids; Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer